<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9831">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788605</url>
  </required_header>
  <id_info>
    <org_study_id>CBMTC-supp001</org_study_id>
    <nct_id>NCT01788605</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Prospective, Single-arm Phase 2 Trial to Evaluate Efficacy and Safety of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The purpose of this study is to determine the efficacy of ramosetron for the prevention
           of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic
           treatment during hematopoietic stem cell transplantation

        2. The study hypothesis is that ramosetron is effective for the prevention of emesis and
           control of emesis and/or vomiting that develop after the prophylactic antiemetic
           therapy in the setting of hematopoietic stem cell transplantation
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>efficacy of ramosetron in terms of complete response (no emesis, no rescue therapy) during the conditioning regimen and within 3 or 6 days after the end of the conditioning regimen</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the efficacy of second dose of ramosetron for the treatment of breakthrough emesis</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>the number of vomiting episodes</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>grade of nausea and need for rescue therapy</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <arm_group_label>ramosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing hematopoietic stem cell transplantation conditioned with highly
             or moderately emetogenic drugs or total body irradiation (TBI) for hematologic
             malignancies

          2. aged over 18 yrs

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          4. patients who are able to take oral medications

          5. patients who get well-informed and sign the consent

        Exclusion Criteria:

          1. Patients complicating

               -  severe hypertension (systolic blood pressure &gt; 210 mmHg or diastolic blood
                  pressure &gt; 120 mmHg)

               -  significant heart disease such as congestive heart failure

               -  renal insufficiency (serum Cr &gt;= 3.0 mg/dL)

               -  liver disease (Aspartate aminotransferase (AST), alanine aminotransferase (ALT)
                  &gt; 3 upper normal limit; alkaline phosphatase (ALP) &gt; 2 upper normal limit)

          2. Patients complicated by conditions such as gastrointestinal obstruction or active
             peptic ulcer causing emesis

          3. Patients with brain tumor, brain metastasis and epilepsy

          4. Patients with the history of extrapyramidal symptom

          5. Patients with the history of allergy to serotonin antagonists

          6. pregnant or lactating women

          7. Patients with drug abuse or psychiatric illness, or patients who are not capable of
             the normal communications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic Blood &amp; Marrow Transplantation Center, Seoul St Mary's Hospital, the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bo-Kyung Kim, RN</last_name>
      <phone>82-50-7448-6371</phone>
      <email>mikaella7@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Ki-Seong Eom, MD</last_name>
      <phone>82-2-2258-6056</phone>
      <email>dreom@catholic.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jong-Wook Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 25, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Ki-Seong Eom, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hematologic malignancies</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>ramosetron</keyword>
  <keyword>emesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
